Streetbeat News

Revenues

AVAV

AeroVironment Inc (NASDAQ:AVAV) shares rose after reporting Q3 financial results that exceeded expectations, with revenue of $186.6 million and EPS of 63 cents, surpassing estimates. The company also provided an optimistic outlook for FY 2024, expecting revenue between $700 million and $710 million and adjusted earnings between $2.69 and $2.83 per share. AeroVironment's growth is driven by strong demand, particularly in the Loitering Munition Systems segment, and a solid funded backlog of $462.8 million.

Portfolio Pulse from Adam Eckert

March 05, 2024 | 2:47 pm

SEMR

SEMrush Holdings, Inc. (NYSE:SEMR) shares dropped after reporting Q4 FY23 results with a 21% Y/Y revenue increase to $83.39 million, beating consensus but with a lower future revenue outlook than expected. The company also reported an EPS of $0.05, surpassing consensus, and anticipates a revenue of $364 million-$368 million for FY24, slightly below the $368.81 million estimate.

Portfolio Pulse from Lekha Gupta

March 05, 2024 | 2:32 pm

WAVD

Firefly Neuroscience, Inc. announced findings from a white paper titled 'Brain Network Analytics (BNA) in the Psychiatric Practice: Real-Life Data Analysis', showcasing the significant impact of its BNA™ Platform on disease management in 2,253 U.S patients. The FDA-approved tool demonstrated improvements in treatment compliance, medication selection, and overall patient outcomes for major depressive disorder, generalized anxiety disorder, and ADHD. Additionally, Firefly is set to merge with WaveDancer, Inc. (NASDAQ:WAVD), pending stockholder approval.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 2:18 pm

SCLX

Scilex Holding Company announced the launch of Gloperba, the first FDA-approved liquid oral colchicine for gout prophylaxis, priced at $595 per 150ml. Set to launch in the first half of 2024, Gloperba targets over 70% of gout patients with comorbid conditions requiring dose adjustments. The U.S. gout treatment market is expected to reach $2.0 billion by 2028. Scilex's direct distribution network and experienced commercial team, which successfully launched ZTlido and Elyxyb, positions it well for Gloperba's distribution.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 2:04 pm

T

Eight analysts have recently updated their ratings on AT&T (NYSE:T), showing a mix of bullish and somewhat bullish perspectives with an average 12-month price target of $22.00, up from $20.33. The updates include raised price targets and new ratings, reflecting a positive outlook on AT&T's performance, particularly noting its revenue growth, strong market capitalization, and effective debt management. The company's core business in wireless services and fixed-line services contributes significantly to its revenue, with a notable presence in Mexico and a 70% equity stake in DirecTV.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 2:00 pm

HAYW

Over the past three months, Hayward Holdings (NYSE:HAYW) received four indifferent analyst ratings. The average 12-month price target was raised to $14.25, up 11.07% from the previous $12.83. Analysts from Stifel, Goldman Sachs, and Jefferies adjusted their price targets, reflecting a positive outlook on the company's performance, including a 7.53% revenue growth and a net margin of 11.15%. However, concerns were noted regarding its ROE and ROA, which are below industry averages.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 2:00 pm

AAPL

Jim Cramer expressed skepticism about Apple Inc's (AAPL) short-term prospects due to ongoing turbulence in its China market, particularly after a 24% drop in iPhone sales in the first six weeks of 2024. He advised waiting for a significant price drop before rebuilding a position in AAPL. Contrarily, analyst Gene Munster is optimistic about Apple's AI potential, predicting a significant earnings impact and a $33 billion annual opportunity.

Portfolio Pulse from Benzinga Neuro

March 05, 2024 | 1:58 pm

SPY

The latest USA Redbook data shows a year-over-year increase of 3.1%, up from the previous 2.7%. This indicates a higher than expected growth in retail sales, which could signal a strengthening consumer spending trend.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:58 pm

LQR

LQR House reported a significant increase in revenue for February 2024, posting $202.406 million compared to $44.864 thousand in the same month the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:49 pm

MAIA

MAIA Biotechnology is nearing completion of its THIO-101 Phase 2 trial, with updates on survival and response data expected soon. The company is exploring treatments for multiple hard-to-treat cancers, including NSCLC, and has developed over 80 THIO-like compounds for its second-generation telomere targeting program. Its pipeline also includes THIO-102 and THIO-103 clinical trials in planning stages, and IND-enabling studies for second-generation agents.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:47 pm